Experimental Glioblastoma Vaccine Shows Promise in Slowing Brain Tumor Growth

Click here to get this post in PDF

In clinical trials, 97% of patients receiving a new glioblastoma vaccine did not experience tumor progression in the six months following treatment. Learn more about the immunotherapy under development.